Table 1.
Patient disposition and demographic characteristics.
Figure 1.
Maintenance prescriptions at diagnosis.
Patients (n = 3199) prescribed maintenance therapy at baseline and 3–6 months excluding patients with no treatment, SABD alone, ICS, and others. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure 2.
Proportions of patients continuing on the same treatment class for 24 months.
a To be included in analysis, patients had to receive a prescription at each 3-month interval. Triple, LABA+LAMA+ICS. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure 3.
Percentage of changes in maintenance medications at the end of the 24 months of follow-up.
Censored indicates no prescription for a COPD maintenance medication during a 3 month interval.
Table 2.
Proportions of patients adding to medication.
Table 3.
Proportions of patients switching to another medication or stepping down treatment.
Table 4.
Percent of patients that progressed to triple therapy within 2 years by index treatment prescribed.